Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma

Recent studies indicate that the abnormal microenvironment of tumors may play a critical role in carcinogenesis, including lung cancer. We comprehensively assessed the number of stromal cells, especially immune/inflammatory cells, in lung cancer and evaluated their infiltration in cancers of different stages, types and metastatic characteristics potential. Immunohistochemical analysis of lung cancer tissue arrays containing normal and lung cancer sections was performed. This analysis was combined with cyto-/histomorphological assessment and quantification of cells to classify/subclassify tumors accurately and to perform a high throughput analysis of stromal cell composition in different types of lung cancer. In human lung cancer sections we observed a significant elevation/infiltration of total-T lymphocytes (CD3+), cytotoxic-T cells (CD8+), T-helper cells (CD4+), B cells (CD20+), macrophages (CD68+), mast cells (CD117+), mononuclear cells (CD11c+), plasma cells, activated-T cells (MUM1+), B cells, myeloid cells (PD1+) and neutrophilic granulocytes (myeloperoxidase+) compared with healthy donor specimens. We observed all of these immune cell markers in different types of lung cancers including squamous cell carcinoma, adenocarcinoma, adenosquamous cell carcinoma, small cell carcinoma, papillary adenocarcinoma, metastatic adenocarcinoma, and bronchioloalveolar carcinoma. The numbers of all tumor-associated immune cells (except MUM1+ cells) in stage III cancer specimens was significantly greater than those in stage I samples. We observed substantial stage-dependent immune cell infiltration in human lung tumors suggesting that the tumor microenvironment plays a critical role during lung carcinogenesis. Strategies for therapeutic interference with lung cancer microenvironment should consider the complexity of its immune cell composition.

[1]  S. Lebecque,et al.  Dendritic Cells Infiltrating Human Non-Small Cell Lung Cancer Are Blocked at Immature Stage1 , 2007, The Journal of Immunology.

[2]  Melissa H Wong,et al.  Tumor microenvironment complexity: emerging roles in cancer therapy. , 2012, Cancer research.

[3]  Michael R Hamblin,et al.  CA : A Cancer Journal for Clinicians , 2011 .

[4]  Yi-Chen Lin,et al.  Tumor-associated macrophages: the double-edged sword in cancer progression. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. H. Schuenemeyer,et al.  Generalized Linear Models (2nd ed.) , 1992 .

[6]  F. Oesch,et al.  Oncogene overexpression in non-small-cell lung cancer tissue prevalence and clinicopathological significance , 2004, Journal of Molecular Medicine.

[7]  C. Powell,et al.  Molecular Biology of Lung Cancer Diagnosis and Management of Lung Cancer , 3 rd ed : American College of Chest Physicians , 2013 .

[8]  E. Mulvey,et al.  Regression analyses of counts and rates: Poisson, overdispersed Poisson, and negative binomial models. , 1995, Psychological bulletin.

[9]  L. Coussens,et al.  De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. , 2005, Cancer cell.

[10]  David A. Hume,et al.  Macrophages as APC and the Dendritic Cell Myth , 2008, The Journal of Immunology.

[11]  K. Calame,et al.  Regulation of plasma-cell development , 2005, Nature Reviews Immunology.

[12]  W. Seeger,et al.  Tumor–stromal interactions in lung cancer: novel candidate targets for therapeutic intervention , 2012, Expert opinion on investigational drugs.

[13]  L. Gleaves,et al.  A Critical Role for Macrophages in Promotion of Urethane-Induced Lung Carcinogenesis , 2011, The Journal of Immunology.

[14]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[15]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[16]  M. Merad,et al.  The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. , 2015, American journal of respiratory and critical care medicine.

[17]  L. Zitvogel,et al.  Lung cancer: potential targets for immunotherapy. , 2013, The Lancet. Respiratory medicine.

[18]  A. Gemma,et al.  Predominant infiltration of macrophages and CD8+ T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer , 2008, Cancer.

[19]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[20]  J. Luketich,et al.  Density of tumor-infiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-small-cell lung cancer tumors. , 2011, The Journal of surgical research.

[21]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[22]  C. Powell,et al.  Molecular biology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.

[23]  W. Seeger,et al.  Macrophage and cancer cell cross-talk via CCR2 and CX3CR1 is a fundamental mechanism driving lung cancer. , 2015, American journal of respiratory and critical care medicine.

[24]  K. O'Byrne,et al.  Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Alberto Mantovani,et al.  Macrophage plasticity and polarization: in vivo veritas. , 2012, The Journal of clinical investigation.

[26]  Douglas Hanahan,et al.  Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .

[27]  V. Boussiotis,et al.  Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation , 2012, Science Signaling.

[28]  P. McCullagh,et al.  Generalized Linear Models, 2nd Edn. , 1990 .

[29]  Craig Murdoch,et al.  The role of myeloid cells in the promotion of tumour angiogenesis , 2008, Nature Reviews Cancer.

[30]  Chris Maloney,et al.  PubMed Central , 2017 .

[31]  Rafael Sirera,et al.  The Role of Tumor-Infiltrating Immune Cells and Chronic Inflammation at the Tumor Site on Cancer Development, Progression, and Prognosis: Emphasis on Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[32]  J. López-González,et al.  Tumor-Induced CD8+ T-Cell Dysfunction in Lung Cancer Patients , 2012, Clinical & developmental immunology.

[33]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[34]  K. Cibulskis,et al.  Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer , 2012, Nature Genetics.

[35]  D. Maric,et al.  Tumor-infiltrating myeloid cells activate Dll4/Notch/TGF-β signaling to drive malignant progression. , 2014, Cancer research.

[36]  Loise M. Francisco,et al.  The PD‐1 pathway in tolerance and autoimmunity , 2010, Immunological reviews.

[37]  A. Yoshizawa,et al.  Stromal plasma cells expressing immunoglobulin G4 subclass in non-small cell lung cancer. , 2013, Human pathology.

[38]  L. Holmberg,et al.  The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. , 2013, Cancer letters.

[39]  A Peer-reviewed, Open-access Publication of the R Foundation for Statistical Computing Contributed Research Articles Programmer's Niche News and Notes , 2011 .

[40]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[41]  N. Martinet,et al.  Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. , 2002, The Journal of laboratory and clinical medicine.

[42]  A. Flahault,et al.  Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome. , 1998, The American journal of pathology.

[43]  T. Dønnem,et al.  Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[44]  E. Ruffini,et al.  Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. , 2009, The Annals of thoracic surgery.

[45]  B. Dahal,et al.  Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. , 2012, American journal of respiratory and critical care medicine.

[46]  S. Pullamsetti,et al.  Adventitial Fibroblasts Induce a Distinct Proinflammatory/Profibrotic Macrophage Phenotype in Pulmonary Hypertension , 2014, The Journal of Immunology.

[47]  M. Capecchi,et al.  Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension , 2014, Nature Medicine.

[48]  Eric R. Ziegel,et al.  Generalized Linear Models , 2002, Technometrics.